108 / 150
Guía OncoSur de diagnóstico y tratamiento del dolor
108
>
Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary
of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast
cancer. J Clin Oncol. 2011;29:1221-7.
Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Co-
chrane Database Syst Rev. 2012;2:CD003474.
Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane
Database Syst Rev. 2002;2:CD002068.
Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Da-
tabase Syst Rev. 2006;18;4:CD006250.
BIBLIOGRAFÍA
1. Cassinello J, González A, Rivera F, et al; SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for
the treatment of bone metastases from solid tumours. Clin Transl Oncol. 2012;14:505-11.
2. Suva LJ, Washam C, Nicholas RW, et al. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev
Endocrinol. 2011;7:208-18.
3. Twamoto J. Transient relief of Metastatic cancer bone pain by oral administration of etidronate. J Bone Miner
Metab. 2002;20:228-34.
4. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus
placebo in patients with breast cancer bone metastases. Bull Cancer. 2001;88:701-7.
5. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/predni-
sone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate
cancer and pain. J Clin Oncol. 2003;21:3335-42.
6. Tripathy D, Body JJ, Bergström B. Review of ibandronate in the treatment of metastatic bone disease: experi-
ence from phase III trials. Clin Ther. 2004;26:1947-59.
7. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective
palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two
randomized, placebo-controlled trials. Cancer. 2000;88:1082-90.
8. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with
placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
J Clin Oncol. 2005;23:3314-21.
9. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment
of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol.
2014;15:114-22.
10. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with
pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or
breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-44.
11. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment
of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase
III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-21.
12. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database
Syst Rev. 2002;2:CD002068.
13. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Data-
base Syst Rev. 2012;2:CD003474.
14. Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst
Rev. 2006;18;4:CD006250.
15. Vadhan-Raj S, von Moos R, Fallowfield LJ, et al. Clinical benefit in patients with metastatic bone disease: results
of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol. 2012;23:3045.